CN118973591A - 包含miR-140的药物组合物及其制备方法 - Google Patents

包含miR-140的药物组合物及其制备方法 Download PDF

Info

Publication number
CN118973591A
CN118973591A CN202380031607.3A CN202380031607A CN118973591A CN 118973591 A CN118973591 A CN 118973591A CN 202380031607 A CN202380031607 A CN 202380031607A CN 118973591 A CN118973591 A CN 118973591A
Authority
CN
China
Prior art keywords
chondrocytes
pharmaceutical composition
auricular
exosome
exosomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380031607.3A
Other languages
English (en)
Chinese (zh)
Inventor
矢永博子
仁科博道
矢永茄津
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Contract Society Bozi Technology
Original Assignee
Contract Society Bozi Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contract Society Bozi Technology filed Critical Contract Society Bozi Technology
Publication of CN118973591A publication Critical patent/CN118973591A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Botany (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380031607.3A 2022-03-28 2023-03-26 包含miR-140的药物组合物及其制备方法 Pending CN118973591A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022051095 2022-03-28
JP2022-051095 2022-03-28
PCT/JP2023/012062 WO2023190271A1 (ja) 2022-03-28 2023-03-26 ｍｉＲ－１４０を含む医薬組成物及びその製造方法

Publications (1)

Publication Number Publication Date
CN118973591A true CN118973591A (zh) 2024-11-15

Family

ID=88201695

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380031607.3A Pending CN118973591A (zh) 2022-03-28 2023-03-26 包含miR-140的药物组合物及其制备方法

Country Status (5)

Country Link
US (1) US20250223561A1 (https=)
EP (1) EP4501338A4 (https=)
JP (1) JP7773257B2 (https=)
CN (1) CN118973591A (https=)
WO (1) WO2023190271A1 (https=)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296832A (en) 2005-10-18 2022-11-01 Nat Jewish Health Process of preparing red blood cells using conditionally immortalized long-term hematopoietic stem cells and erythropoietin
EP1969147B1 (en) 2006-01-05 2014-07-30 The Ohio State University Research Foundation microRNA-based methods for the diagnosis of stomach cancer
EP2623599B1 (en) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
US9901600B2 (en) 2011-03-11 2018-02-27 Children's Medical Center Corporation Methods and compositions relating to mesenchymal stem cell exosomes
US9550977B2 (en) 2011-12-02 2017-01-24 Gunze Limited Method for producing auricular cartilage tissue
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
EP3029140A4 (en) 2013-07-30 2017-06-28 Kyoto Prefectural Public University Corporation Corneal endothelial cell marker
WO2016076102A1 (ja) 2014-11-14 2016-05-19 株式会社リジェネシスサイエンス 軟骨細胞の無血清培養方法，及び無血清培地
HK1257561A1 (zh) 2015-11-05 2019-10-25 株式会社Cysay 永生化干细胞及其制作方法
JP2017108650A (ja) 2015-12-15 2017-06-22 国立大学法人名古屋大学 家畜視床下部繁殖中枢由来不死化神経細胞株
WO2017195268A1 (ja) 2016-05-10 2017-11-16 株式会社アイシーエレクトロニクス ｍｉＲＮＡをマーカーとする歯周炎検査キット、及び検査方法
KR20180092348A (ko) * 2017-02-09 2018-08-20 주식회사 엑소코바이오 연골세포로 분화되고 있는 제대 및 제대혈 유래 줄기세포로부터 분리된 엑소좀을 포함하는 연골세포 분화 유도 또는 연골조직 재생용 조성물
JP6948059B2 (ja) 2017-09-28 2021-10-13 学校法人 川崎学園 ｍｉＲ−１４０−３ｐによる骨芽細胞からのオステオカルシン産生促進
WO2019093308A1 (ja) 2017-11-09 2019-05-16 国立大学法人広島大学 ｍｉＲＮＡを含むがん治療用医薬組成物
GB201718681D0 (en) 2017-11-13 2017-12-27 Evox Therapeutics Ltd Protein engineered extracellular vesicles
KR102123903B1 (ko) * 2018-08-13 2020-06-17 전북대학교산학협력단 분화인자가 함유된 엑소좀 나노 캐리어 조성물 및 이의 제조방법
US20220062348A1 (en) 2018-09-19 2022-03-03 Yeditepe Universitesi Isolated septal cartilage exosome used for generating cartilage tissue

Also Published As

Publication number Publication date
JP7773257B2 (ja) 2025-11-19
US20250223561A1 (en) 2025-07-10
JPWO2023190271A1 (https=) 2023-10-05
EP4501338A1 (en) 2025-02-05
WO2023190271A1 (ja) 2023-10-05
EP4501338A4 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
EP3594348B1 (en) C/ebp alpha short activating rna compositions and methods of use
EP3037092B1 (en) Composition containing monoacetyldiglyceride compound as active ingredient for inhibiting blood cancer
US20210254069A1 (en) Combination therapies comprising c/ebp alpha sarna
CN116782948A (zh) 包含长双歧杆菌rapo（kctc13773bp）的用于预防或治疗癌症的组合物
JP2022505327A (ja) Ｓｙｔ１１抑制剤を有効成分として含む胃癌治療用組成物
TW202128203A (zh) 預防癌症復發的組成物及方法
CN111208283A (zh) 增效的肿瘤抑制组合物及其应用
WO2020101212A1 (ko) 편도 유래 중간엽 줄기세포의 조정 배지를 포함하는 암 전이 억제용 조성물
CN118973591A (zh) 包含miR-140的药物组合物及其制备方法
US12071622B2 (en) miR-3132 upregulation of the trail pathway and apoptotic activity in cancer cells
CN117122606A (zh) 淫羊藿次苷i在治疗或预防微卫星稳定型实体瘤中的应用及包含其的药盒
CN108653291A (zh) Thz1在治疗卵巢癌中的用途
JP2021028297A (ja) マイクロｒｎａ及びその誘導体を有効成分とするがん治療剤
CN114917243A (zh) 金诺芬用于制备治疗急性t淋巴细胞白血病药物的用途
CN116509854B (zh) 一种萘啶酮衍生物的应用
CN121337784B (zh) 3-羟基戊二酸在制备预防和/或治疗高尿酸相关疾病的药物中的应用及防治药物
TW202529742A (zh) 組合物、篩選方法及組合物之製造方法
CN113917146B (zh) 人pole2基因的用途及相关产品
CN119753149A (zh) 一种抗胰腺癌靶点camk2a及其在制备胰腺癌治疗药物中的应用
Jia et al. Inhibitory effects of STAT3 inhibitor WP1066 on proliferation of MYCN amplified neuroblastoma cells
CN113917144A (zh) 人sh2d2a基因的用途及相关产品
HK40070347A (en) C/ebp alpha short activating rna compositions and methods of use
GB2594084A (en) Medical methods and medical uses
CN119857143A (zh) Cd84作为治疗靶点在制备防治炎症性肠病的药物中的应用
CN113913513A (zh) 人dsn1基因的用途及相关产品

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination